Objectives.The purpose of this study was to use standard gamble (SG) utility interviews to assess parent preferences for health states of childhood attention-deficit/hyperactivity disorder (ADHD).Methods.The study was conducted in August 2003 in London, England. Parents (N = 83) of children diagnosed with ADHD completed SG utility interviews, rating their child’s current health and 14 hypothetical health states describing untreated ADHD and ADHD treated with a nonstimulant, immediate-release stimulant, or extended-release stimulant. Raw temporary utilities ranging from 0 (worst health) to 1 (best health) were adjusted to a chronic utility scale ranging from 0 (death) to 1 (best health) using a linear transformation. Parents rated the severity of their children’s ADHD symptoms using the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS) and their children’s health-related quality of life using the EuroQol EQ-5D.Results.Raw and adjusted SG ratings of hypothetical health states ranged from 0.63-0.90 and 0.88-0.96, respectively. Parents’ raw SG scores of their child’s current health state (mean = 0.72) were significantly correlated with inattentive, hyperactive, and overall ADHD symptoms (r = -0.25, -0.27, -0.27; P < 0.05) and the EQ-5D visual analogue scale (r = 0.26; P < 0.05).Conclusion.This UK-based study suggests that parent SG interviews are a valid method for obtaining utilities for child ADHD-related health states. The utilities obtained in this study would be appropriate for use in a cost-utility analysis evaluating the costs and benefits of childhood ADHD treatments in the United Kingdom.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington (DC): American Psychiatric Press; 2000.
2.
World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-10). 10th rev. ed.Geneva: World Health Organization; 1992.
3.
Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 2nd ed.New York: Guilford; 1998.
4.
Barkley RA, DuPaul GJ, McMurray MB. Comprehensive evaluation of attention deficit disorder with and without hyperactivity as defined by research criteria. J Consult Clin Psychol. 1990;58:775-789.
5.
Barkley RA, Anastopoulos AD, Guevremont DC, Fletcher KE. Adolescents with ADHD: patterns of behavioral adjustment, academic functioning, and treatment utilization. J Am Acad Child Adolesc Psychiatry. 1991;30:752-761.
6.
Hinshaw RD, Melnick SM. Peer relationship in boys with attention deficit hyperactivity disorder with and without comorbid aggression. Dev Psychopathol. 1995;7:627-647.
7.
Matza LS, Rentz AM, Secnik K, et al. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2004; 25:166-174.
8.
Sawyer MG, Whaites L, Rey JM, Hazell PL, Graetz BW, Baghurst P. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry. 2002;41:530-537.
9.
Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics. 2001;107:E43.
10.
Esser G, Schmidt MH, Woerner W. Epidemiology and course of psychiatric disorders in school-age children—results of a longitudinal study. J Child Psychol Psychiatry. 1990;31:243-263.
11.
Graetz BW, Sawyer MG, Hazell PL, Arney F, Baghurst P. Validity of DSM-IV ADHD subtypes in a nationally representative sample of Australian children and adolescents. J Am Acad Child Adolesc Psychiatry. 2001;40:1410-1417.
12.
Scahill L, Schwab-Stone M. Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am. 2000;9:541-555, vii.
13.
Szatmari P, Offord DR, Boyle MH. Ontario Child Health Study: prevalence of attention deficit disorder with hyperactivity. J Child Psychol Psychiatry. 1989;30:219-230.
14.
DuPaul GJ, Barkley RA, Connor DF. Stimulants. In: Barkley RA, ed. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 2nd ed.New York: Guilford; 1998.
15.
Reid R, Hakendorf P, Prosser B. Use of psychostimulant medication for ADHD in South Australia. J Am Acad Child Adolesc Psychiatry. 2002;41:906-913.
16.
Romano E, Baillargeon RH, Wu HX, Robaey P, Tremblay RE. Prevalence of methylphenidate use and change over a two-year period: a nationwide study of 2- to 11-year-old Canadian children. J Pediatr. 2002;141:71-75.
17.
Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35:409-432.
18.
Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 2000;9:573-603, viii.
19.
Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003;157:17-25.
20.
Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:E83.
21.
Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry. 2002;63(Suppl 12):16-22.
22.
Spencer TJ, Biederman J, Wilens TE, Faraone SV. Overview and neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63:3-9.
23.
Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1-30.
24.
Torrance GW. Designing and conducting cost-utility analyses. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed.Philadelphia: Lippincott-Raven; 1996.
25.
Feeny D, Barr RD, Furlong W, Torrance GW, Weitzman S.Quality of life of the treatment process in pediatric oncology: an approach to measurement. In: Osaba D, ed. Effect of Cancer on Quality of Life. Boca Raton (FL): CRC Press; 1991.
26.
Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoecon Outcomes Res. 2002;2:99-108.
27.
Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health. 1999;2:113-127.
28.
Patrick DL, Chiang YP. Measurement of health outcomes in treatment effectiveness evaluations: conceptual and methodological challenges. Med Care. 2000;38:1114-1125.
29.
Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf. 2001;10:85-94.
30.
Lord J, Paisley S.The Clinical Effectiveness and Cost-Effectiveness of Methylphenidate for Hyperactivity in Childhood, Version 2. London: National Institute for Clinical Excellence; 2000.
31.
Brooks R, Rabin R, de Charro F, eds. The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Dordrecht: Kluwer Academic; 2003.
32.
Matza LS, Secnik K, Rentz AM, et al. Development and assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Qual Life Res. In press.
33.
Gafni A. The standard gamble method: what is being measured and how it is interpreted. Health Serv Res. 1994;29:207-224.
34.
Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5:559-575.
35.
National Institute for Clinical Excellence. Guidance on the use of methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. Retrieved 20 January 2004 from http://www.nice.org.uk/pdf/Methylph-guidance13.pdf.
36.
Sayal K, Taylor E, Beecham J, Byrne P. Pathways to care in children at risk of attention-deficit hyperactivity disorder. Br J Psychiatry. 2002;181:43-48.
37.
Klasen H, Goodman R. Parents and GPs at cross-purposes over hyperactivity: a qualitative study of possible barriers to treatment. Br J Gen Pract. 2000;50:199-202.
38.
Petrou S. Methodological issues raised by preference-based approaches to measuring the health status of children. Health Econ. 2003;12:697-702.
39.
Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.
40.
Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyper-activity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
41.
Sutton V, Sumner C, Allen AJ, Feng W, Schuh K, Michelson D.Validity, reliability, and responsiveness of the DPREM-R Scale for ADHD. American Academy of Child and Adolescent Psychiatry; 2003 Oct 14-19; Miami, FL.
42.
Gillberg C, Lothgren M, Fitzgerald P, et al. Atomoxetine versus methylphenidate as a treatment for ADHD in children and adolescents: a meta-analysis of safety data incorporating active comparator and placebo controlled trials. European Society for Child and Adolescent Psychiatry; 2003 Sep 28-Oct 7; Paris, France.
43.
Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R.Treatment of Attention-Deficit/Hyperactivity Disorder. Evidence Report/Technology Assessment No. 11. Rockville (MD): Agency for Healthcare Research and Quality; 1999.
44.
Miller A, Lee SK, Raina P, Klassen A, Zupancic J, Olsen L.A Review of Therapies for Attention-Deficit/Hyperactivity Disorder. Ottawa: Canadian Coordinating Office For Health Technology Assessment; 1999.
45.
Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001; 107:E105.
46.
Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165:1475-1488.
47.
Swanson J, Gupta S, Lam A, et al. Development of a new once-aday formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60:204-211.
48.
Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:883-892.
49.
DuPaul GJ, Power TJ, Anastopoulos AD, Reid R.ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: Guilford; 1998.
50.
Landgraf JM, Maunsell E, Speechley KN, et al. Canadian-French, German, and UK versions of the child health questionnaire: methodology and preliminary item scaling results. Qual Life Res. 1998;7:433-445.
51.
Landgraf JM, Abetz LN, Ware JE. The CHQ User’s Manual. Boston: HealthAct; 1999.
52.
Electronic Medicines Compendium (eMC). Summary of product characteristics. Available from http://www.medicines.org.uk/emc.aspx.
53.
Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord. 1998;48:25-36.
54.
Bass EB, Steinberg EP, Pitt HA, et al. Comparison of the rating scale and the standard gamble in measuring patient preferences for outcomes of gallstone disease. Med Decis Making. 1994;14:307-314.
55.
Cook J, Richardson J, Street A. A cost utility analysis of treatment options for gallstone disease: methodological issues and results. Health Econ. 1994;3:157-168.
56.
Johnston K, Brown J, Gerard K, O’Hanlon M, Morton A. Valuing temporary and chronic health states associated with breast screening. Soc Sci Med. 1998;47:213-222.
57.
Stalmeier PF. Discrepancies between chained and classic utilities induced by anchoring with occasional adjustments. Med Decis Making. 2002;22:53-64.
58.
Kadesjo C, Kadesjo B, Hagglof B, Gillberg C. ADHD in Swedish 3- to 7-year-old children. J Am Acad Child Adolesc Psychiatry. 2001;40:1021-1028.
59.
Magnusson P, Smari J, Gretarsdottir H, Prandardottir H. Attention-deficit/hyperactivity symptoms in Icelandic schoolchildren: assessment with the Attention Deficit/Hyperactivity Rating Scale-IV. Scand J Psychol. 1999;40:301-306.
60.
EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
61.
Krabbe P, Weijnen T.Guidelines for analysing and reporting EQ-5D outcomes. In: Brooks R, Rabin R, de Charro F, eds. The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Dordrecht: Kluwer Academic; 2003.
62.
McDowell I, Newell C.Measuring Health: A Guide to Rating Scales and Questionnaires. 2nd ed.New York: Oxford University Press; 1996.
63.
Cohen J.Statistical Power Analysis for the Behavioral Sciences. 2nd ed.Hillsdale (NJ): Lawrence Erlbaum; 1988.
64.
Torrance GW. Preferences for health outcomes and cost-utility analysis. Am J Manag Care. 1997;3:S8-S20.
65.
Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed.Oxford (UK): Oxford University Press; 2000.
